Mark G. Kris
0000-0002-7317-5341
Publication & Citation Trends
Publications
0 total
A Phase II Study of Cabozantinib in Patients With MET-Altered Lung Cancers
Cited by 0
Semantic Scholar
P3.18.11 Adding Certolizumab to Neoadjuvant Chemoimmunotherapy - Control of Immune-Related Adverse Events and Prevention of Surgical Delays
Cited by 0
Semantic Scholar
P3.03.01 Rb Inactivation as a Hallmark of Squamous Transformation in EGFR-Mutant Lung Cancers
Cited by 0
Semantic Scholar
P1.07.37 Using Tissue and Blood to Find Oncogenic Drivers Upfront in Patients With Lung Cancer Evaluated for Neoadjuvant Therapy-LEADER
Cited by 0
Semantic Scholar
Durvalumab Concurrent and Following Thoracic Radiotherapy vs. Concurrent Chemoradiotherapy and Consolidation Durvalumab in Locally Advanced Non-Small Cell Lung Cancer: A Propensity Matched Analysis of a Prospective Trial
Cited by 0
Semantic Scholar
Outcomes with neoadjuvant osimertinib and/or chemotherapy in patients with EGFR-mutant resectable non-small cell lung cancers.
Cited by 0
Semantic Scholar
OA09.01 Machine Learning Assessment of Pathologic Response in Lung Resections After Neoadjuvant Therapy - IASLC MPR Project
Cited by 0
Semantic Scholar
P2.06.12 TP53/RB1-Mutant Squamous Cell Lung Cancers: Clinicopathologic Features and Outcomes
Cited by 0
Semantic Scholar
Research Topics
Lung Cancer Treatments and Mutations
(943)
Lung Cancer Research Studies
(427)
Lung Cancer Diagnosis and Treatment
(254)
Cancer Genomics and Diagnostics
(216)
Cancer Immunotherapy and Biomarkers
(168)
Affiliations
AstraZeneca (United Kingdom)
Broad Institute
Northwestern University
University of North Carolina at Chapel Hill
University of Southern California